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OBJECTIVES We investigated the association between seropositivity to chlamydial lipopolysaccharide
(cLPS) or Chlamydia pneumoniae (CP) and angiographically documented coronary artery
disease (CAD), and we examined the relationship between serostatus and markers of systemic
inflammation.
BACKGROUND The potential contribution of CP to atherogenesis is still a matter of debate, and inflammation
has been suggested to represent the link between infection and atherosclerotic disease.
METHODS Subjects age 40 to 68 years were recruited for this case-control study between October 1996
and November 1997: 312 patients with at least one coronary stenosis .50% and 479 age- and
sex-matched blood donors without manifest CAD or history of angina. Antibodies against
cLPS and CP, C-reactive protein (CRP), fibrinogen, plasma viscosity, leukocytes and
neutrophils were determined. The study had a power of .80% to detect an odds ratio (OR)
of 1.55 or above for the prevalence of immunoglobulin (IgG) antibodies against cLPS at a
significance level of alpha 5 0.05.
RESULTS Prevalence of IgG antibodies against cLPS was not different between cases and controls (61%
vs. 62%; p 5 0.7). The adjusted OR for the presence of CAD given positive IgG serostatus
against cLPS was 0.9 (95% CI; 0.6 to 1.3). Similarly, no difference in the prevalence of IgG
antibodies against CP was seen (88% vs. 87%; p 5 0.6); the adjusted OR was 1.0 (95% CI;
0.6 to 1.6). Markers of inflammation did not show any statistically significant difference
between cLPS seropositives and seronegatives.
CONCLUSIONS Our results indicate no strong association between CP and CAD, and increased systemic
inflammation in patients with CAD does not seem to be due to seropositivity to cLPS or CP.
(J Am Coll Cardiol 2000;35:112–8) © 1999 by the American College of Cardiology
Evidence of a potential role of infectious agents in the
pathogenesis of atherosclerosis has been reported in several
studies (see references [1–3] for recent reviews of the
literature). In particular, an infection with Chlamydia pneu-
moniae (CP) has been claimed to be associated with athero-
sclerotic cardiovascular disease in seroepidemiological (4–6)
and angiographical studies (7–10). Furthermore, CP has
been detected in atheromatous lesions of coronary arteries
(11–14), yet the importance of these findings is still unclear.
The organism may be actively involved in atherogenesis as a
primary inducing agent or may exacerbate an existing
inflammatory process. It cannot be ruled out, however, that
CP is not involved in the process, but rather represents an
innocent bystander passively brought to the site by mono-
cytes.
Most of the previous seroepidemiological studies have
reported a moderately strong association between CP and
coronary artery disease (CAD). However, because of small
sample size, results were statistically not significant in
several of them, and often adequate control for potential
confounders had not been carried out. Because the prefer-
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ential publication of positive studies may have led to a
publication bias, larger well-controlled studies are necessary
to support or reject the hypothesis of an association between
CP and CAD.
We therefore conducted a large case-control study to
assess the association of angiographically documented CAD
with seropositivity to chlamydial lipopolysaccharide (cLPS)
and CP. Furthermore, because it has been suggested that
systemic inflammation represents a link between infection
and pathogenesis of atherosclerosis (1,2,15), we measured a
variety of acute-phase reactants and related them to serosta-
tus.
METHODS
Study design. This case-control study was done in a
university hospital setting in southern Germany. Subjects
age 40 to 68 years and of German nationality were recruited
between October 1996 and November 1997. Cases and
controls were matched for age and sex; a sampling ratio of
about 1:1.5 was intended. All subjects underwent blood
sampling and a standardized interview. The study was
approved by the ethics committee of the University of Ulm.
Informed consent was obtained from all participants.
Subjects. Cases were recruited in the University Hospital
of Ulm. All subjects had a CAD with at least one coronary
stenosis .50% at catheterization within the previous six
months before entry into the study. Patients with acute
coronary syndromes during the previous four weeks were
excluded. The diagnosis “CAD” had been established no
longer than two years earlier for the first time. Voluntary
blood donors from the associated Red Cross blood bank
served as controls. Potential controls with manifest heart
disease or a history of angina pectoris according to the Rose
angina questionnaire were excluded. Further exclusion cri-
teria for cases and controls were acute infection, acute state
of a chronic infectious or inflammatory disease, anticoagu-
lant therapy (i.e., full-dose heparin or coumarins) during the
preceding four weeks, severe liver or renal disease, neoplasm
and hematological disorders.
Laboratory. Blood was taken under standardized condi-
tions, and a complete blood cell count was done. The
remaining blood was centrifuged at 3,000g for 10 min
within 30 min and aliquoted immediately. Plasma and
serum specimens were frozen and stored at 270°C until
analysis. All laboratory determinations were done in a
blinded fashion. Antibodies (IgM, IgG, IgA) against Chla-
mydia species (chlamydial lipopolysaccharide) were mea-
sured by a recombinant enzyme linked immunoassay
(ELISA) (16) (Medac, Wedel, Germany). This ELISA
used a cLPS antigen produced by recombinant DNA
technology. This antigen contains a common epitope shared
by all Chlamydia species (17). An IgG titre $100 was
defined as seropositive ($50 for IgM and IgA). Determi-
nations of specific antibodies against CP were performed by
microimmunofluorescence method as described elsewhere
(18). An IgG titer $64 was considered to be seropositive
($16 for IgA). C-reactive protein measurement was done
by an immunoradiometric assay (range 0.05 to 10 mg/liter)
calibrated with the WHO (World Health Organization)
reference standard 85/506. Fibrinogen was measured by
immunonephelometry (Behring, Marburg, Germany) and
by the Clauss method. Measurement of plasma viscosity was
done by a Coulter Harkness capillary viscometer (19).
Leukocytes and neutrophils were counted automatically in a
Coulter STKS chamber (Coulter, Krefeld, Germany). The
intra-assay coefficient of variation was 4% for CRP, 3.7% for
fibrinogen and 0.7% for plasma viscosity.
Questionnaire. A standardized questionnaire was applied
to all cases and controls by the same trained team of
interviewers. It included a history of cardiovascular risk
factors, history of heart disease and particular symptoms of
angina pectoris according to the Rose questionnaire, current
medication, previous antibiotic therapy, alcohol intake,
physical activity and further socioeconomic variables.
Statistical analysis. Cases and controls were compared
according to baseline characteristics in a descriptive way.
The association of seropositivity to cLPS and CP with
presence of CAD was analyzed using a chi-square statistic.
To assess differences in the distribution among various
categories of each variable in seropositives, a chi-square
statistic was also performed. We used the Wilcoxon rank-
sum test to compare markers of inflammation between
seropositive and seronegative subjects. Multivariable logistic
regression was performed to assess the independent associ-
ation of a seropositive status against cLPS and CP with
CAD; we controlled for age, gender, body mass index
(BMI), pack years of smoking, history of hypertension,
history of diabetes, years of school education, and alcohol
consumption. Data were analyzed using SAS statistical
software package (version 6.12).
RESULTS
Characteristics of the study population. In this study, 791
subjects (312 cases and 479 controls) were enrolled. Re-
sponse rate among cases was 78% and among controls 84%.
Table 1 shows demographic characteristics and classical risk
factors of the study population. Mean BMI, pack years of
Abbreviations and Acronyms
BMI 5 body mass index
CAD 5 coronary artery disease
cLPS 5 chlamydial lipopolysaccharide
CP 5 Chlamydia pneumoniae
CRP 5 C-reactive protein
ELISA 5 enzyme linked immunoassay
IgG/A/M 5 immunoglobulin G/A/M
MIF 5 microimmunofluorescence
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smoking, and prevalence of subjects with history of hyper-
tension, dyslipidemia and diabetes as well as low school
education were higher in cases than in controls (all p ,
0.01). No significant differences were found for alcohol
consumption, family status and history of chronic bronchitis.
Nearly two-thirds of the cases (62%) had a history of
previous myocardial infarction within the previous two
years. Based on the results of coronary angiography, 48%
had a one-vessel disease, 34% a two-vessel disease and 18%
a three-vessel disease.
Seroprevalence. IgG antibodies against cLPS were present
in 62% of all subjects, and the prevalence of IgA antibodies
against cLPS was 36%. The IgG antibodies against CP were
found in 87% of all participants; the overall prevalence of
IgA antibodies against CP was 36%. Table 2 shows that the
prevalence of IgG (IgA) antibodies against cLPS or CP was
not significantly different between cases and controls, inde-
pendent of the serological cutoff point chosen (Fig. 1). The
prevalence of IgG antibodies against cLPS in cases with
previous myocardial infarction was 63%, and in cases with-
out infarction 56% (p 5 0.2). The prevalence of IgG
antibodies against cLPS in cases with one-vessel disease was
64%, with two-vessel disease 56% and with three-vessel
disease 61% (p 5 0.4).
Seroprevalence, classical risk factors and socioeconomic
variables. Most of the classical risk factors of CAD and of
the socioeconomic variables were not related to the serosta-
tus against cLPS (Table 3). A positive serostatus was less
frequent in women than in men (p 5 0.004). No significant
positive association was detectable between age and serosta-
tus in the age range 40 to 68 years (p 5 0.2). Patients with
history of diabetes revealed significantly fewer antibodies
against cLPS compared to patients without such a history
(p 5 0.04).
Seropositivity and risk of CAD. Table 4 shows the
association of cLPS and CP with CAD after adjustment for
age, gender and potential other confounders by multiple
logistic regression. There was no increased risk of CAD
associated with the presence of IgG or IgA antibodies
against cLPS or CP in adjusted analyses. Furthermore,
taking high levels of antibody titres into consideration did
not change the results.
Inflammation and serostatus. In Table 5, mean values of
different markers of systemic inflammation are compared
with serostatus against cLPS. None of the variables showed
a statistically significant difference between seropositives
and seronegatives, neither in cases nor in controls. By
contrast, a consistently increased inflammatory activity was
seen in patients with CAD compared to controls.
The same results were found comparing markers of
systemic inflammation by serostatus to CP (seronegative,
IgG 64–511, and IgG $ 512).
DISCUSSION
Key findings. In this study, the prevalence of IgG or IgA
antibodies against cLPS or CP did not differ between
angiographically defined cases with CAD and carefully
selected age- and gender-matched controls. This was true
even when high antibody titres were considered as cutoff.
Furthermore, the history of a previous myocardial infarction
and severity of CAD was not associated with an increased
seroprevalence. The results of bivariate analysis were also
confirmed after controlling for various covariables by means
of logistic regression, which revealed no strong and inde-
pendent association between seropositivity to cLPS or CP
and stable CAD. Thus, these findings do not confirm the
results from several previous studies (4–10).
Table 1. Characteristics of the Study Population (n 5 791)
Cases
(n 5 312)
Controls
(n 5 479)
Male (%) 85.6 75.0
Mean age (yrs) 6 SD 57.7 6 7.4 55.8 6 7.2
Mean BMI (kg/m2) 6 SD 27.3 6 3.6 26.3 6 3.2
Smoking status
Current (%) 9.6 14.2
Past (%) 66.3 42.0
Never (%) 24.0 43.8
Smoked pack years 20.3 10.8
History of
Hypertension (%) 57.7 20.5
Dyslipidemia (%) 67.3 20.9
Diabetes (%) 13.5 2.7
Daily alcohol consumption (%) 29.5 28.6
School education ,10 yrs (%) 69.2 58.5
Married (%) 85.9 83.9
History of chronic bronchitis (%) 9.0 5.8
Table 2. Prevalence of Antibodies Against Chlamydial LPS and
Chlamydia pneumoniae in Cases and Controls
Antibody
Titre
Cases
(n 5 312)
(%)
Controls
(n 5 479)
(%)
p
Value*
Chlamydial
LPS
IgG >100 60.9 62.4 0.3
IgG 100–399 41.7 42.0
IgG $400 19.2 20.5 0.3†
IgA >50 38.5 35.1 0.5
IgA 50–199 25.6 25.7
IgA $200 12.8 9.4 0.2†
IgM >50 3.9 2.3 0.2
C. pneumoniae IgG >64 87.4 86.2 0.9
IgG 64–511 32.9 38.1
IgG $512 54.4 48.1 0.5†
IgA >32 38.1 35.3 0.5
IgA 32–127 35.6 30.5
IgA $128 2.5 4.8 0.9†
*Adjusted for age and gender. †Test for trend.
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Seroepidemiological evidence. In 1988, Saikku et al. (4)
reported for the first time an association of CP with chronic
CAD and acute myocardial infarction in a small study from
Finland. Later, Saikku et al. (5) confirmed their findings
using a nested case-control design in which subjects were
identified from the Helsinki Heart Study; serum samples
were obtained three to six months before a cardiac end point
(n 5 103) had occurred, and they were compared with
matched controls. After adjustment for age, hypertension,
and smoking, the odds ratio (OR) for developing a cardiac
end point was 2.3 (95% CI, 0.9 to 6.2) for an elevated IgA
titre ($64) against CP, but only 1.5 (95% CI, 0.7 to 3.2) for
elevated IgG titres ($128) against CP, and 1.8 (95% CI, 0.9
to 3.6) for cLPS-containing immune complexes. These
differences were not statistically significant, but they indi-
cated a trend, that the presence of CP antibodies together
with cLPS-containing immune complexes might be a risk
factor for CAD. Miettinen et al. (20) found an independent
positive association between seropositivity to CP and CAD
in a cohort study from eastern Finland only in nondiabetics,
but not in a population from western Finland.
In a cross-sectional study, Patel et al. (6) investigated a
population-based random sample of 388 male London
inhabitants. The OR for having electrocardiographic abnor-
malities suggestive of CAD or a history of angina or
myocardial infarction, given seropositivity to CP (IgG $
64), was 2.2 (95% CI, 1.1 to 4.6) after adjustment for several
potential confounders.
No association between seropositivity to CP and CAD
was reported in a large population-based case-control study
from Israel for the first time in which potential confounders
were carefully controlled for (21). This study included 302
patients with first acute myocardial infarction and 486 age-
and gender-matched controls. The prevalence of anti-CP-
IgG ($32) was 81% in male patients (85% in male controls)
and 65% in female patients (69% in female controls). The
prevalence of anti-CP-IgA ($20) was 47% in male patients
(45% in male controls) and 20% in female patients (22% in
female controls). Recent prospective data from the Physi-
cians’ Health Study also showed no evidence of an associ-
ation between positive anti-CP-IgG titre and future coro-
nary risk (22).
Results from all these studies were based on clinical signs
of CAD and did not use coronary angiography to charac-
terize their cases.
Two case-control studies from Seattle, Washington, had
included patients with angiographically documented CAD
(7,8). In the first study, patients without angiographically
detectable CAD (n 5 95) served as controls and were
compared to 461 cases (7). The investigators estimated a
relative risk of CAD for subjects with positive IgG anti-
bodies against CP of 1.6 (95% CI; 1.0 to 2.7). In the second
Figure 1. Distribution of the prevalence of IgG antibodies against Chlamydia pneumoniae by different titres based on microimmunoflu-
orescence (MIF) in cases and controls (n 5 791).
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study, population-based controls (n 5 120) without CAD
by history were included and compared with 171 cases (8).
An adjusted OR of 4.2 (95% CI; 1.8 to 10.0) for a positive
antibody titre against CP was found. In both studies,
adjustment was carried out only for age, gender, and month
of blood drawing, but not for smoking behavior and other
potential confounders.
Only high positive CP-IgG and IgA titres were related to
angiographically defined CAD in a study from London (9)
that included 170 subjects. A large study from northern
Germany (10), with 412 cases and 431 unmatched controls,
found a crude OR for angiographically defined CAD, given
positive IgG antibodies against CP of 2.4 (95% CI, 1.6 to
3.7), but no adjustments for potential confounders were
performed, although the controls were on average 20 years
younger than the cases.
Systemic inflammation and infection with CP. Various
potential pathophysiological mechanisms relating infectious
agents to atherogenesis have been postulated (1–3)—that is,
an increased production of cytokines (IL-6 or IL-1) and
acute-phase reactants, a local or systemic disturbance of
fibrinolysis and blood coagulation, a direct infection of the
arterial wall via macrophages and alteration of vascular cell
function and an immunological response (cross reaction)
due to bacterial heat-shock protein. However, the potential
importance and the mediating mechanisms of chlamydial
infection in atherogenesis are only incompletely understood.
In the second part of the study we investigated the
association between various markers of systemic inflamma-
tion and seropositivity to cLPS and CP. The CRP has been
measured by an immunoradiometric assay that is able to
detect values well below the clinically relevant range. How-
ever, seropositivity to cLPS or CP was not associated with
elevated CRP concentrations; neither was there an associa-
tion between other inflammatory markers and antibodies
against cLPS or CP. These results are in contrast to findings
by Patel et al. (6), who reported elevated levels of fibrinogen
in patients with a clinical or ECG diagnosis of CAD and a
positive serostatus to CP. A recently published report by
Anderson et al. (23) showed a borderline significant asso-
ciation between elevated CRP and combined seropositivity
to Helicobacter pylori and CP, but not to CP alone. Also, no
relationship between CRP concentrations and levels of IgG
antibody titre against CP was found in the Physicians’
Health Study (22).
Study strengths and limitations. Our study included a
relatively large number of patients and had a power of
.80% (.84%) to detect an OR of 1.55 or above for an
increased IgG (IgA) antibody titre against cLPS at a
significance level of alpha 5 0.05. Moreover, careful adjust-
ment was made for potential confounders. It is widely
recognized that higher age and male sex are positively
associated with the prevalence of antibodies to CP (24,25);
the prevalence rises from about 20% in teenagers to about
Table 3. Prevalence of IgG Antibodies Against Chlamydial LPS
in Relation to Classical Risk Factors and Socioeconomic
Variables in the Study Population (n 5 791)
Variable Status n
IgG >100
(%)
p
Value
Gender Male 626 64.4
Female 165 52.1 0.004
Age (yrs) 40–49 175 58.3
50–59 309 60.2
60–68 307 65.5 0.2
BMI (kg/m2) ,24.2 194 60.3
$24.2–26.4 199 63.3
$26.4–28.4 198 58.1
$28.4 197 66.0 0.4
Smoked pack years None 311 57.6
0–5.5 83 67.5
$5.5–22.8 199 59.8
$22.8 198 68.2 0.06
History of
Hypertension Yes 278 59.3
No 513 63.2 0.3
Dyslipidemia Yes 310 60.0
No 481 63.0 0.4
Diabetes Yes 55 49.1
No 736 62.8 0.04
Alcohol consumption Daily 228 61.4
No 93 62.4
Sometimes 467 61.9 0.9
School education ,10 yrs 499 61.5
$10 yrs 292 62.3 0.8
Total — 791 61.8 —
Table 4. Association of Chlamydial LPS and Chlamydia
pneumoniae with CAD
Risk Factor
Odds Ratio (95%
Confidence Interval)
Adjusted for
Age and
Gender
Adjusted for
Multiple
Covariates*
Chlamydial LPS (IgG ,100) 1reference 1reference
(IgG >100) 0.8 (0.6–1.2) 0.9 (0.6–1.3)
(IgG 100–399) 0.9 (0.6–1.2) 1.0 (0.6–1.4)
(IgG $400) 0.8 (0.5–1.2) 0.7 (0.4–1.2)
Chlamydial LPS (IgA ,50) 1reference 1reference
(IgA >50) 1.1 (0.8–1.5) 1.1 (0.8–1.6)
(IgA 50–199) 1.0 (0.7–1.4) 1.1 (0.7–1.6)
(IgA $200) 1.3 (0.8–2.1) 1.2 (0.7–2.3)
C. pneumoniae (IgG ,64) 1reference 1reference
(IgG >64) 1.0 (0.6–1.5) 1.0 (0.6–1.6)
(IgG 64–511) 0.8 (0.5–1.3) 0.8 (0.5–1.3)
(IgG $512) 1.0 (0.7–1.6) 1.1 (0.7–1.8)
C. pneumoniae (IgA ,32) 1reference 1reference
(IgA >32) 1.1 (0.8–1.5) 1.1 (0.8–1.5)
*Adjusted for age, gender, BMI, smoking status, alcohol consumption, school
education years, history of hypertension and diabetes.
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60% to 80% in subjects aged 40 to 80 years (24,25).
Cigarette smoking also seems to be positively associated
with chlamydial infection (6,26).
We included only cases with a diagnosis of CAD estab-
lished during the two preceding years, documented either by
myocardial infarction or coronary angiography. This was
done to minimize potential selection bias by selective
survival, and to focus on a potential association between the
first appearance of CAD and serostatus. Because patients
with an acute coronary syndrome have elevated markers of
systemic inflammation, we enrolled only patients with stable
CAD. The choice of blood donors as controls is generally
suboptimal, because blood donors probably tend to be
healthier than population-based controls. However, results
as reported in the present study without statistically signif-
icant differences of prevalence against CP antibodies be-
tween both groups give further support to our conclusions.
A limitation of the present study was the inability to
perform an ECG or coronary angiography in controls, so
that asymptomatic CAD in controls cannot be ruled out.
However, prevalence of CAD in asymptomatic middle-aged
subjects appears to be low (for review, see Parmley [27]),
and selection of controls among subjects who undergo
coronary angiography for different reasons would possibly
introduce more severe bias if these conditions were related
to CP infection.
It is unclear in what way antibodies reflect previous or
current chronic or latent infection of CP. Although sero-
logical criteria have been suggested for chronic CP infection,
they have not been validated against the presence of DNA
in atherosclerotic plaques or mononuclear cells in the blood.
However, we have used two different serological tests with
almost entirely consistent results. First, the MIF method is
able to detect specific antibodies against CP, which persist
for a long time. This may explain a higher prevalence of
specific CP antibodies as compared with antibodies against
cLPS, which has also been reported by others (4,28). The
MIF method may perform differently in different laborato-
ries. Our method has been compared with that of several
well-experienced laboratories and seems to produce specific
antibody results. Second, we have used a genus-specific
rELISA against cLPS (including Chlamydia trachomatis and
C. psittaci), which may be particularly useful for acute (re-)
infection (17). This rELISA test is commercially available
and reliably standardized. This test is not specific for CP;
however, the prevalence of IgG antibodies against C.
trachomatis and C. psittaci is low (in the present study 7%
and ,1%, respectively).
SUMMARY
Our data do not support an important role of CP in
atherogenesis. The prevalence of antibodies against cLPS
and CP was almost identical in cases and controls, in cases
with or without previous myocardial infarction and in cases
with one-, two- or three-vessel disease. However, it cannot
be excluded that, in patients with atherosclerosis, CP mod-
ulates an inflammatory process after reaching the athero-
sclerotic plaques by macrophages attracted to the site of
active inflammation and that this process might not be
detectable by serology. Recently, viable CP has been de-
tected in human atherosclerotic lesions (29), and in an
experimental cholesterol-feeding rabbit model, CP induced
progression of atherosclerosis (30). However, it may be a
significant observation of our study that this suggested
inflammatory effect of CP does not lead to an increase in
systemic inflammatory activity. Moreover, prior or chronic
infection with Chlamydia species does not explain the
elevation of inflammatory markers, which were consistently
found in patients with CAD (for review, see Danesh et al.
[31]) and which we were also impressed to see in the present
study.
Table 5. Markers of Systemic Inflammation in Relation to Serostatus Against Chlamydial LPS in Cases and Controls
Group Parameter
Seropositive
Mean (SD)
Seronegative
Mean (SD) p Value
Cases (n 5 312) C-reactive protein (mg/liter)† 1.70 1.53 0.6
Fibrinogen (g/liter)
Clauss method 2.78 (0.62) 2.83 (0.71) 0.9
Nephelometric 2.83 (0.59) 2.81 (0.69) 0.7
Plasma viscosity (mPaps) 1.224 (0.066) 1.224 (0.064) 0.9
Leukocytes (103/ml) 6.7 (1.7) 7.0 (1.8) 0.2
Neutrophils (103/ml) 3.9 (1.2) 4.2 (1.5) 0.1
Controls (n 5 479) C-reactive protein (mg/liter)† 1.13 1.13 0.9
Fibrinogen (g/liter)
Clauss method 2.59 (0.61) 2.58 (0.57) 0.6
Nephelometric 2.53 (0.66) 2.49 (0.50) 0.7
Plasma viscosity (mPaps) 1.194 (0.056) 1.185 (0.047) 0.1
Leukocytes (103/ml) 5.7 (1.4) 5.7 (1.6) 0.6
Neutrophils (103/ml) 3.6 (1.1) 3.7 (1.2) 0.6
†Geometric mean.
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In conclusion, this case-control study did not confirm a
strong association between CAD and antibodies to the
common cLPS antigens or specific antibodies to CP. Fur-
thermore, seropositivity to cLPS or CP was not associated
with an increased systemic inflammatory activity. Therefore,
these findings, based on a serological approach, do not
support an important role of CP in atherogenesis.
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